SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Integrum Reports 97.9% One-Year OPRA Implant Survival

A study of 49 Ukrainian war-injured amputees found 97.9% implant survival 12 months after S2 with Integrum’s OPRA Implant System. Infections occurred in 18% during the first year; median follow-up was 18.7 months, with 93.2% survival.

INTEGB
SquawkNews Desk

Related stories

Viatris Commences Tender Offer to Acquire Pacira BioSciences M impact | EQUITY | Oct 30, 2026, 01:03 PM UTC LyondellBasell Reports Higher Third-Quarter Revenue, Warns Middle East Recovery Will Be Slow LyondellBasell reported higher quarterly revenue and said Middle East conditions will likely remain fluid. The body is truncated before details on a potential return to pre-conflic M impact | EQUITY | Oct 30, 2026, 12:59 PM UTC JPMorgan Downgrades Coursera to Neutral, Cuts Target to $5 JPMorgan lowered its price target from $8 to $5. The new target implies 7.3% upside from Coursera’s Oct. 29 close of $4.66. M impact | EQUITY | Oct 30, 2026, 12:56 PM UTC BofA Downgrades Intel to Neutral, Cuts Price Target to $100 BofA lowered its rating on Intel from Buy to Neutral and reduced its price target from $145 to $100. M impact | EQUITY | Oct 30, 2026, 12:33 PM UTC Regeneron Shares Rise More Than 8% Premarket After Q3 Earnings Beat Regeneron reported stronger-than-expected third-quarter earnings, supported by demand for its eye treatments and higher collaboration revenue from Sanofi. Shares gained more than 8 M impact | EQUITY | Oct 30, 2026, 12:31 PM UTC European session market picture: S&P 500 -1.1%, Nasdaq 100 -2.59%; EUR/USD +0.1%, WTI +1.86%, LLOY leads volume European session market picture. US index futures: S and P futures is down 1.1 percent, Nasdaq futures is down 2.59 percent, Dow futures is down 0.1 percent and Russell futures is M impact | EQUITY | Oct 30, 2026, 12:30 PM UTC